Vaccines against respiratory infections may shield the heart

The European Parliament is currently reviewing a strategy for managing cardiovascular disease that observers say misses a vital connection: the role of vaccination against respiratory infections in heart health. While the SANT Committee draft report published on 19 January 2026 outlines various approaches for the bloc, it fails to integrate immunisation as a preventive measure for cardiac conditions.

This oversight creates a disconnect between parliamentary efforts and existing executive guidelines. The European Commission, through its EU Safe Hearts Plan, explicitly identifies respiratory immunisation as a tool for lowering the incidence of heart-related ailments. That plan even proposes a specific Council Recommendation to formalize this preventive approach.

For the average patient, this policy gap means that systemic care may remain fragmented rather than unified. If medical guidelines fail to bridge the divide between lung-focused immunisation and heart-focused treatment, individuals living with underlying conditions might miss out on simple, high-impact preventive care that could otherwise be integrated into routine visits.

Clearer policy alignment would help clinicians offer more detailed guidance during standard check-ups. The Active Citizenship Network is now pushing for a shift in this legislative stance. The organisation, along with various stakeholders including scientific societies and professional associations, has proposed amendments to the draft report. They argue that the current document requires adjustment before it reaches a plenary vote.

Policy integration remains a priority for long-term health outcomes.

A scheduled meeting at the European Parliament in Brussels on 18 March aims to address these concerns. Hosted by Cypriot MEP Michalis Hadjipantela, the event is titled “Council recommendation on the value of immunisation against respiratory infections: a step towards an EU Respiratory Health Plan?“. It serves as a platform for experts and institutional representatives to discuss how immunisation fits into a broader health framework. This approach is central to the upcoming dialogue.

The discussion occurs amid a wider shift in European Union immunisation policy. The European Medicines Agency has recommended the first combined vaccine for people aged 50 years and older, targeting both seasonal influenza and COVID-19. Additionally, the European Commission has committed €225 million toward developing next-generation flu shots that are easier to administer and adaptable to emerging strains.

Legislators will have to decide whether to incorporate these tools into the final cardiovascular disease strategy. The current debate reflects a push from civil society to move past siloed medical approaches. With the vote approaching, the Steering Group on Prevention of Respiratory Infections continues to advocate for a more cohesive response to public health challenges.

The event itself is part of the “Advancing Respiratory Care at the EU Level“ project. This initiative received support from Pfizer, according to the filing. Attendees are expected to explore how these recommendations could eventually shape a future unified health policy.